Alcon AG

Regulatory Filings • Apr 21, 2011

15-12B 1 a11-7954_41512b.htm 15-12B

*UNITED STATES*

*SECURITIES AND EXCHANGE COMMISSION*

*Washington, D.C. 20549*

*FORM 15*

*CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 .*

Commission File Number: 001-31269

*ALCON, INC.*

(Exact name of registrant as specified in its charter)

*Bösch 69, P.O. Box 62*

*Hünenberg, Switzerland*

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

*Common Shares, par value CHF 0.20 per share*

(Title of each class of securities covered by this Form)

*None*

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)	o
Rule 12g-4(a)(2)	o
Rule 12h-3(b)(1)(i)	x
Rule 12h-3(b)(1)(ii)	o
Rule 15d-6	o

Approximate number of holders of record as of the certification or notice date: ZERO (0)

Explanatory Note : By virtue of the direct merger of Alcon, Inc. with and into Novartis AG, completed on April 8, 2011, Novartis AG, as successor to Alcon, Inc., has assumed Alcon, Inc.’s reporting obligation under Section 15(d) of the Securities Exchange Act of 1934.

Pursuant to the requirements of the Securities Exchange Act of 1934, Novartis AG, as successor to Alcon, Inc., has caused this certification/notice to be signed on its behalf by the undersigned duly authorized persons.

Date:
By:	/s/ Dr. Thomas Werlen
Name:	Dr. Thomas Werlen
Title:	Group General Counsel
By:	/s/ Jonathan Symonds
Name:	Jonathan Symonds
Title:	Chief Financial Officer

SEQ.=1,FOLIO='',FILE='C:\JMS\C900688\11-7954-4\task4629621\7954-4-ba.htm',USER='C900688',CD='Apr 21 17:24 2011'